<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Platelet-derived <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> may occur during <z:hpo ids='HP_0004944'>intracranial aneurysm</z:hpo> coiling </plain></SENT>
<SENT sid="1" pm="."><plain>We report a series of 13 patients treated with intraarterial Abciximab for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation complicating <z:hpo ids='HP_0002617'>aneurysm</z:hpo> coiling </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Four patients were treated for acutely ruptured <z:hpo ids='HP_0002617'>aneurysms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Three procedures consisted of the retreatment of previously coiled <z:hpo ids='HP_0002617'>aneurysms</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Six patients had asymptomatic untreated <z:hpo ids='HP_0002617'>aneurysms</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Abciximab was administered intraarterially through a microcatheter as a bolus of 4-10 mg over a period of 10-20 minutes </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent postthrombolysis control angiography </plain></SENT>
<SENT sid="7" pm="."><plain>They also underwent immediate pre- and postoperative cranial CT </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In 10/13 cases, the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> developed without coil protrusion into the parent artery </plain></SENT>
<SENT sid="9" pm="."><plain>In one case, the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was generated from the guiding catheter and embolized remote from the <z:hpo ids='HP_0002617'>aneurysm</z:hpo> site </plain></SENT>
<SENT sid="10" pm="."><plain>In one case, the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> developed before any coil placement </plain></SENT>
<SENT sid="11" pm="."><plain>In another patient, a coil loop protruded into the parent artery favoring a heightened thrombotic state </plain></SENT>
<SENT sid="12" pm="."><plain>Arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were totally occlusive in two patients, whereas in the remaining 11 cases, the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were not totally obstructive </plain></SENT>
<SENT sid="13" pm="."><plain>Complete recanalization was achieved in 92% (12/13) of cases within 20-30 minutes </plain></SENT>
<SENT sid="14" pm="."><plain>Incomplete arterial reopening was noted in one case, in which a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> fragment embolized distally, causing <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>There were no Abciximab-related <z:hpo ids='HP_0002170'>intracranial hemorrhages</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: Intraarterial Abciximab was effective in this series for the treatment of thrombotic complications occurring during <z:hpo ids='HP_0002617'>aneurysm</z:hpo> coiling </plain></SENT>
</text></document>